Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Kailera Therapeutics, Inc. (KLRA)

12.89 +1.46 (+12.77%)
At close: 4:00:01 PM EDT
12.89 0.00 (0.00%)
After hours: 5:00:52 PM EDT
Chart Range Bar
Loading chart for KLRA
  • Previous Close 11.43
  • Open 11.43
  • Bid 9.37 x 200
  • Ask 14.78 x 200
  • Day's Range 11.43 - 13.06
  • 52 Week Range 9.76 - 28.23
  • Volume 1,576,006
  • Avg. Volume 960,739
  • Market Cap (intraday) 1.671B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -4.51
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 42.40
  • Zacks Rating Neutral

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

www.kailera.com

145

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/20/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KLRA
50.42%
S&P 500 (^GSPC)
12.67%

1-Year Return

KLRA
50.42%
S&P 500 (^GSPC)
14.51%

3-Year Return

KLRA
50.42%
S&P 500 (^GSPC)
82.58%

5-Year Return

KLRA
50.42%
S&P 500 (^GSPC)
70.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -78.86M
Profit Margin 0.00%

Q1

FY26

-60M
-40M
-20M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

30.00
42.40 Average
12.89 Current
57.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/12/2026
Analyst Leerink Partners
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 36

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    1.70B

  • Enterprise Value

    795.70M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.52

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -292.2M

  • Diluted EPS (ttm)

    -4.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    916.74M

  • Total Debt/Equity (mrq)

    0.91%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

12.89 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: